InSights Hub

Medications

Showing 10 results in Medications

What's Changed ADHD In Children & Adolescents

Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents – What’s Changed

Attention Deficit Hyperactivity Disorder (ADHD) affects an estimated 7 million (11.4%) children in the United States aged 3–17 years, as reported in a national survey of parents conducted in 2022. Nearly 6 in 10 children diagnosed with ADHD experience moderate to severe symptoms. Disturbingly, approximately 2 million children with ADHD did not receive specialized treatment […]

Read More
Upcoming FDA Approvals & Decisions

Upcoming FDA Decisions – October 2024

The Food and Drug Administration (FDA) protects public health by guaranteeing the safety, effectiveness, and security of pharmaceuticals and medical devices. The Prescription Drug User Fee Act (PDUFA) date marks the deadline by which the FDA must complete its review of drug applications. Occasionally, an advisory committee (AdCom) meeting is convened to assess the drug […]

Read More
What's Changed Mild Intermittent Asthma in Adults

Mild Intermittent Asthma in Adults – What’s Changed

Intermittent asthma, or mild intermittent asthma, stands as the most prevalent form of asthma. Recent data from the Centers for Disease Control (CDC) reveals that over 20 million adults in the United States have been diagnosed with asthma. Among them, 8 million have encountered one or more asthma attacks within the past year, with 9% […]

Read More
Upcoming FDA Approvals & Decisions - September 2024

Upcoming FDA Decisions – September 2024

The Food and Drug Administration (FDA) protects public health by guaranteeing the safety, effectiveness, and security of pharmaceuticals and medical devices. The Prescription Drug User Fee Act (PDUFA) date marks the deadline by which the FDA must complete its review of drug applications. Occasionally, an advisory committee (AdCom) meeting is convened to assess the drug […]

Read More
What's Changed Uncomplicated Urinary Tract Infections (UTIs) in Women

Uncomplicated Urinary Tract Infections in Women – What’s Changed

Patients with uncomplicated urinary tract infections (UTIs) do not have any structural abnormalities in their urinary tract or comorbidities such as diabetes, an immunocompromised state, recent urologic surgery, or pregnancy. An uncomplicated UTI is also referred to as cystitis or a lower tract UTI. It is estimated that approximately half of all women will experience […]

Read More
What's Changed & Predictions Gout

Gout – What’s Changed Since+ Predictions

Gout is a common medical condition characterized by the accumulation of monosodium urate (MSU) monohydrate crystals in the tissues, often resulting in painful flares that can last for one to two weeks. According to the National Institutes of Health (NIH), gout is more prevalent in men than in women and typically presents in middle age. […]

Read More
Guidelines Timeline - AAO Dry Eye Syndrome

Comparing the AAO Dry Eye Syndrome Preferred Practice Pattern – Guidelines Timeline

The American Academy of Ophthalmology (AAO) is the largest association of eye physicians and surgeons globally. Their mission is to protect vision and enhance quality of life by establishing the benchmarks for ophthalmic education and championing the interests of patients and the general public.   AAO regularly releases Preferred Practice Pattern® guidelines (PPP) aimed at defining […]

Read More

Dapagliflozin (Farxiga/AZ) – Guidelines+ Monographs (August 2024 Edition)

In this edition of our Guidelines Monographs Series, we will be taking a look at AstraZeneca’s medication dapagliflozin, brand name Farxiga. Initially approved in 2014, Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, provided to individuals with diabetes, heart disease, or kidney disease to improve their outcomes. This Guidelines+ Monograph will take a deeper dive […]

Read More
« Back to InSights Hub